

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE AS FOLLOWS:

- Sub  
B1
- Sub A1
- FOR F.O. E. 150367
1. A process of making a solid pharmaceutical composition comprising moexipril magnesium, said process comprising the step of reacting moexipril or an acid addition salt thereof with an alkaline magnesium compound in the presence of a solvent so as to convert most or all of the moexipril or moexipril acid addition salt to moexipril magnesium.
  2. A process of Claim 1 comprising the steps of:
    - i) Adding the moexipril or acid addition salt thereof and the alkaline magnesium compound to solvent and mixing in the liquid state;
    - ii) Evaporating the solvent to obtain a dried material, and
    - iii) Further processing the dried material into the solid pharmaceutical composition.
  3. A process of Claim 2 wherein, before the solvent is evaporated, the liquid is filtered to remove unreacted alkaline magnesium compound.
  4. A process of Claim 2 or 3 wherein the solvent is evaporated by spray-drying.
  5. A process of Claim 1 comprising the steps of:
    - i) adding the moexipril or acid addition salt thereof and the alkaline magnesium compound to solvent;

- Sub A1
- ii) using the resultant solution or suspension to wet granulate other excipients to obtain a wet mass;
- iii) drying the wet mass to obtain a dried mass; and
- iv) further processing the dried mass into the solid pharmaceutical composition.

6. A process of Claim 1 comprising the steps of:

- i) adding the alkaline magnesium compound to solvent;
- ii) using the resulting solution or suspension to wet granulate a mixture of the moexipril or acid addition salt thereof and one or more excipients to obtain a wet mass;
- iii) drying the wet mass to obtain a dried mass; and
- iv) further processing the dried mass into the solid pharmaceutical composition.

7. A process of Claim 1 comprising the steps of:

- i) adding the moexipril or acid addition salt thereof to solvent;

FOOTED E2T60860

Sub A1

- ii) using the resultant solution or suspension to wet granulate a mixture of the alkaline magnesium compound and one or more other excipients to obtain wet mass;
  - iii) drying the wet mass to obtain a dried mass, and
  - iv) further processing the dried mass into the solid pharmaceutical composition.
8. A process of Claim 1 comprising the steps of:
- i) mixing the moexipril or acid addition salt thereof and alkaline magnesium compound with one or more other excipients;
  - ii) adding a solvent and mixing to obtain a wet mass;
  - iii) drying the wet mass to obtain a dry mass; and
  - iv) further processing the dried mass into the solid pharmaceutical composition.
9. A process of any of Claims 1 to 8 where the solvent is selected from a group of solvents comprising water, an organic solvent, acetone, or combinations thereof.
10. A process of any of Claims 1 to 8 wherein the moexipril or acid addition salt thereof is moexipril hydrochloride.

TOP SECRET

Sub A1

11. A process of any of Claims 1 to 8 wherein the alkaline magnesium compound is selected from the group of compounds comprising magnesium hydroxide, magnesium oxide, magnesium carbonate, or the magnesium salt of a weak acid.
12. A process of any of Claims 1 to 8 wherein the percentage of the moexipril or acid addition salt converted to moexipril magnesium is substantially greater than about 80%.
13. A process of any of Claim 12 wherein the percentage of the moexipril or acid addition salt thereof converted to moexipril magnesium is substantially greater than 90%.
14. A solid pharmaceutical composition comprising moexipril magnesium.

Add A2

FOIA b 7 - DATED 03-16-01